Key result
Anakinra induces sustained remission of massive chronic pericardial effusion through 12 months post-discontinuation.
Why the study?
Consensus guidelines for managing isolated idiopathic pericardial effusion in children are lacking, and the role of interleukin-1 receptor antagonists when standard therapies fail in the absence of classic inflammatory markers was unreported.
Does subcutaneous anakinra resolve massive, treatment-refractory idiopathic pericardial effusion with elevated pericardial fluid IL-6 levels in a pediatric patient?
Case Report (n=1)
No
Does subcutaneous anakinra resolve massive, treatment-refractory idiopathic pericardial effusion with elevated pericardial fluid IL-6 levels in a pediatric patient?
Cytokine profiling of pericardial fluid can uncover localized hyperinflammation in chronic idiopathic pericardial effusion lacking systemic inflammatory signs, identifying pediatric patients who may achieve sustained remission with IL-1 receptor antagonist therapy (anakinra).
Answers are grounded in this paper and cite their sources.
May support anakinra in select refractory pediatric cases with IL-6 elevation; leaves open confirmation in prospective trials.
We report a child with massive, chronic idiopathic pericardial effusion (PE), initially detected incidentally and asymptomatically. Despite multiple treatment attempts, including Nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and repeated pericardiocentesis, the effusion persisted and recurred. Advanced imaging revealed a stable but severe PE over the years, with no hemodynamic compromise. Cytokine analysis of the pericardial fluid showed markedly elevated interleukin (IL)-6 levels, suggesting an underlying inflammatory process despite the absence of classic clinical signs. Based on this finding, the patient was successfully treated with anakinra, an IL-1 receptor antagonist, resulting in sustained remission for 24 months. This case highlights the potential role of biologic therapy in selected pediatric patients with chronic idiopathic PE, even when traditional markers of inflammation are absent. Cytokine profiling may help identify candidates for anti-IL-1 treatment, providing a valuable therapeutic option where standard approaches fail.
No takes yet. Share an insight, caveat, or question.
Pasquinucci et al. (2026) conducted a case report in Massive, chronic idiopathic pericardial effusion (n=1). Anakinra was evaluated on Remission and recurrence of pericardial effusion. Anakinra induced sustained remission of a massive 3.3 L chronic idiopathic pericardial effusion for 24 months of treatment and 12 months after discontinuation in a pediatric patient.
Synapse has enriched 10 related papers. Consider them for comparative context: